Drug intelligence / Profile preview

131I-A6H

Development stage: Discontinued
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

131I-A6H is a radiolabeled monoclonal antibody consisting of the A6H antibody conjugated with Iodine-131, a radioactive isotope. This was investigated as a radioimmunotherapy agent for renal cell carcinoma (RCC). The A6H monoclonal antibody was designed to target antigens associated with RCC, while the Iodine-131 component provides beta and gamma radiation for therapeutic effect. According to available information, the use of mAb A6H for diagnosis and treatment of RCC was discontinued[5]. Iodine-131 emits approximately 90% beta radiation and 10% gamma radiation, with a half-life of approximately 8 days.

Other names: [131I]A6H

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on 131I-A6H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 131I-A6H.

Explore the full profile